SwanBio Therapeutics is a gene therapy company developing leading-edge medicines to deliver dramatic clinical efficacy for the treatment of neurological diseases. Founded by proven industry leaders with a commitment to positively impacting the lives of people with neurological diseases, SwanBio merges clinical, scientific and drug commercialization expertise.

SwanBio is using adeno-associated virus (AAV) to deliver therapeutic genes directly to the central nervous system to achieve rapid and profound therapeutic effects. AAV has been shown to be safe and effective in multiple clinical trials. SwanBio is developing an AAV-based gene therapy for a rare inherited neurodegenerative disease in which the causative gene is definitively known and well characterized. While their initial focus is on diseases that are both rare and serious, the broader vision is understanding the origin and treatment of disorders where therapeutic DNA has the potential to treat neurological illnesses.

SwanBio Therapeutics is dedicated to developing genetic medicines for the treatment of serious neurological diseases with significant unmet need. Driven by an unrelenting passion to solve difficult challenges, and a belief that meaningful discovery is born of curiosity, collaboration, and compassion.